The inventive method for producing an antitumoral vaccine using endothelial cells, consists in exposing live endothelial cells to a protease action which is vital therefor and in extracting the released surface antigens. The live endothelial cells are repeatedly treated with protease at intervals necessary for restoring the surface antigens by the cells, the surface antigens are accumulated until the dose thereof, necessary for vaccination, is obtained and the quality of the thus obtained vaccine is verified. Said invention makes it possible to increase the efficiency of oncological disease treatment by damaging tumoral vessels by overpassing the immune tolerance of the body to the endothelial cells of the tumoral vessels. The invention keeps in mind the overpassing of immune tolerance, in particular to activated endothelial cells, thereby making it possible to damage the immune system, in particular of tumoral vessels.
